---
title: "AXPAXLI (axitinib intravitreal implant) in Neovascular age-related macular degeneration: References"
description: "Reference list for the formulary evidence report on AXPAXLI (axitinib intravitreal implant, OTX-TKI) in Neovascular age-related macular degeneration. 308 cited documents."
canonical: "https://www.evicenter.com/drugs/axpaxli--neovascular-age-related-macular-degeneration/references"
published: "2026-09-17T18:54:38-04:00"
modified: "2026-11-17T22:33:35-05:00"
---

# AXPAXLI (axitinib intravitreal implant) in Neovascular age-related macular degeneration: References

<a id="references"></a>

## 5 References

1. [4DMT second-quarter 2026 results announcement (2026)](https://ir.4dmoleculartherapeutics.com/news-releases/news-release-details/4dmt-reports-second-quarter-2026-financial-results-operational)
2. [Abu Al-Burak et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41812994/)
3. [Acharya et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13448695/)
4. [Age-Related Eye Disease Study 2 Research Group (2013)](https://pubmed.ncbi.nlm.nih.gov/23644932/)
5. [Age-Related Eye Disease Study 2 Research Group (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5866182/)
6. [Age-Related Eye Disease Study Research Group (2001)](https://pmc.ncbi.nlm.nih.gov/articles/PMC1462955/)
7. [Agrón et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11416341/)
8. [Al-Khersan et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35636743/)
9. [Almony et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391196/)
10. [Ambresin et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40692491/)
11. [American Academy of Ophthalmology](https://www.aao.org/advocacy/issues/administrative-burden/step-therapy)
12. [American Academy of Ophthalmology IRIS63 measure specification](https://www.aao.org/medicare/quality-reporting-measure/iris63-exudative-age-related-macular-degeneration)
13. [American Society of Retina Specialists Preferences and Trends Survey (2026)](https://www.asrs.org/asrs-community/pat-survey/results-new/1078?evergreen=staff)
14. [Amin and Kaiser (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13084661/)
15. [Amoaku et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4469673/)
16. [Anastasopoulos et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/17157603/)
17. [AREDS2-HOME Study Research Group (2014)](https://pubmed.ncbi.nlm.nih.gov/24211172/)
18. [Augustin et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17389477/)
19. [Avery (2023)](https://investors.ocutx.com/static-files/00a24bfa-e147-49fc-86cf-9135b9e4f37f)
20. [Bailey et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30301555/)
21. [Bakri et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11149885/)
22. [Baljoon et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13194801/)
23. [Banister et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35119357/)
24. [Barakat et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11426123/)
25. [Berkowitz and Patel (2021)](https://pubmed.ncbi.nlm.nih.gov/32818623/)
26. [Berkowitz et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31219520/)
27. [Blizzard et al. (2024)](https://investors.ocutx.com/static-files/4ab97f8b-adf0-4acf-8e3d-2bd7c1441fb2)
28. [Bloch et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22264944/)
29. [Boyle et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/28064517/)
30. [Bressler et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20189654/)
31. [Bressler et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9857301/)
32. [Brody et al. (2001)](https://pubmed.ncbi.nlm.nih.gov/11581068/)
33. [Brown et al. (2000)](https://pubmed.ncbi.nlm.nih.gov/10636413/)
34. [Brown et al. (2002)](https://pubmed.ncbi.nlm.nih.gov/11934322/)
35. [Brown et al. (2005)](https://pmc.ncbi.nlm.nih.gov/articles/PMC1447589/)
36. [Brown et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/17021319/)
37. [Brown et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26249730/)
38. [Brown et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32565050/)
39. [Brown et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32681907/)
40. [Brown et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37981235/)
41. [Brown et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39182627/)
42. [Bryan et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12592112/)
43. [Butler et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12531612/)
44. [CADTH (2022)](https://www.ncbi.nlm.nih.gov/books/NBK602699/)
45. [CADTH reimbursement recommendation (2022)](https://www.cda-amc.ca/sites/default/files/DRR/2022/SR0719REC-Vabysmo.pdf)
46. [Campochiaro et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39209113/)
47. [Castillo et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4268457/)
48. [CATT Research Group (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3157322/)
49. [CATT Research Group (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3389193/)
50. [CDA-AMC (2024)](https://www.ncbi.nlm.nih.gov/books/NBK610414/)
51. [CDA-AMC reimbursement recommendation (2024)](https://www.cda-amc.ca/sites/default/files/DRR/2024/SR0812_Eylea_HD_nAMD-Final_Rec.pdf)
52. [Centers for Medicare & Medicaid Services (2018)](https://www.cms.gov/Medicare/Health-Plans/HealthPlansGenInfo/Downloads/MA_Step_Therapy_HPMS_Memo_8_7_2018.pdf)
53. [Chakravarthy et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3009619/)
54. [Chakravarthy et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23870813/)
55. [Chandra et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10697959/)
56. [Cheung et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32795496/)
57. [Chew et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9164119/)
58. [Choi et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10746973/)
59. [Ciulla et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31324588/)
60. [Clemons et al. (2004)](https://pmc.ncbi.nlm.nih.gov/articles/PMC1473208/)
61. [ClinicalTrials.gov NCT03630315](https://clinicaltrials.gov/study/NCT03630315)
62. [ClinicalTrials.gov NCT04989699](https://clinicaltrials.gov/study/NCT04989699)
63. [ClinicalTrials.gov NCT06223958](https://clinicaltrials.gov/study/NCT06223958)
64. [ClinicalTrials.gov NCT06495918](https://clinicaltrials.gov/study/NCT06495918)
65. [ClinicalTrials.gov NCT07516132](https://clinicaltrials.gov/study/NCT07516132)
66. [Comparison of Age-related Macular Degeneration Treatments Trials Research Group (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4958614/)
67. [Congdon et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/15078664/)
68. [Cornish et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32310628/)
69. [Cruess et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18088159/)
70. [DailyMed BEOVU prescribing information (2024)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5d1dc1fa-a2d3-46ed-9e9a-c1a036590d3d)
71. [DailyMed BYOOVIZ prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e46db299-edd1-4457-89b2-c1e2e505f1b0)
72. [DailyMed CIMERLI prescribing information (2024)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b383d74-4830-4587-95f7-c32a39268df7)
73. [DailyMed EYLEA HD prescribing information (2026)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=86d8848b-111b-4da9-8957-7cccef1b8f66)
74. [DailyMed EYLEA prescribing information (2024)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f96cfd69-da34-41ee-90a9-610a4655cd1c)
75. [DailyMed INLYTA prescribing information (2024)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84137882-e000-47da-bd5b-fa76ab3c76f9)
76. [DailyMed LUCENTIS prescribing information (2024)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de4e66cc-ca05-4dc9-8262-e00e9b41c36d)
77. [DailyMed PAVBLU prescribing information (2026)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c61062f3-80ec-4a20-8c28-46e468592a06)
78. [DailyMed SUSVIMO prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9c6d9e2a-9a77-4d11-b692-de87cfde3444)
79. [DailyMed VABYSMO prescribing information (2026)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04cc9ef7-c02a-4e92-a655-0062674e8487)
80. [DailyMed VISUDYNE prescribing information (2021)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=952f4c80-50b1-4308-9ee6-311ffefb13df)
81. [Daniel et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3943618/)
82. [Daniel et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6015772/)
83. [Danzig et al. (2025)](https://investors.ocutx.com/static-files/63e2624d-379a-40e3-99bd-9a00e49a1e30)
84. [Dawson et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4094542/)
85. [Day et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3219793/)
86. [Delcourt et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13460392/)
87. [Dhoot (2025)](https://pubmed.ncbi.nlm.nih.gov/40505850/)
88. [Dhoot et al. (2022)](https://investors.ocutx.com/static-files/2ede9647-0109-4b51-b204-823d19cbaa86)
89. [Dhoot et al. (2026)](https://investors.ocutx.com/static-files/846aebd1-a507-40b5-b92a-3f60c66c3b11)
90. [Dickson and James (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10492178/)
91. [Do et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22297028/)
92. [Dugel et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/30986442/)
93. [Dugel et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32574761/)
94. [Eichenbaum et al. (2024)](https://investors.ocutx.com/static-files/a6148d04-e289-40c0-9b2b-233c22ec0458)
95. [Eichenbaum et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39154860/)
96. [El Alili et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12901786/)
97. [Emami-Naeini et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37866681/)
98. [Emerson et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9976064/)
99. [Espallargues et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/16249475/)
100. [EyePoint LUGANO topline announcement (2026)](https://www.globenewswire.com/news-release/2026/08/17/3345965/0/en/eyepoint-announces-topline-data-from-lugano-the-first-of-two-pivotal-phase-3-clinical-trials-for-duravyu-2-7mg-in-wet-amd.html)
101. [Faes et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7005831/)
102. [FDA Biosimilar Product Information (2026)](https://www.fda.gov/drugs/biosimilars/biosimilar-product-information)
103. [Ferris et al. (2005)](https://pmc.ncbi.nlm.nih.gov/articles/PMC1473206/)
104. [Ferris et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11551519/)
105. [Finger et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7368708/)
106. [Finn et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37855832/)
107. [Flaxel et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31757502/)
108. [Fleckenstein et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12878645/)
109. [Fleckenstein et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12935482/)
110. [Franco and Wubben (2026a)](https://pubmed.ncbi.nlm.nih.gov/41490387/)
111. [Franco et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/42479493/)
112. [Frank et al. (1996)](https://pubmed.ncbi.nlm.nih.gov/8794712/)
113. [Freund et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18301024/)
114. [Friedman et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/15078675/)
115. [Fritsche et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4745342/)
116. [Gale et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10084380/)
117. [Gale et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41861959/)
118. [Garmo et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10981881/)
119. [GBD 2019 Blindness and Vision Impairment Collaborators (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7820391/)
120. [GBD 2021 Global AMD Collaborators (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12208786/)
121. [Genentech (2024)](https://www.gene.com/media/press-releases/15031/2024-07-08/genentech-to-reintroduce-susvimo-for-peo)
122. [Genentech (2025)](https://www.gene.com/media/press-releases/15073/2025-08-01/genentechs-susvimo-maintains-vision-over)
123. [Gibson (2025)](https://investors.ocutx.com/static-files/0ca6958b-a3aa-44ef-9603-9d7c85a7a865)
124. [Giddabasappa et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26927930/)
125. [Gillies et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26096346/)
126. [Gismero Moreno et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12506087/)
127. [Gohil et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4461306/)
128. [Gragoudas et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/15625332/)
129. [Grunwald et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5234734/)
130. [Hanemoto et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/29220371/)
131. [Heier (2026)](https://investors.ocutx.com/static-files/288573d0-ca9a-470a-9954-dcee3f1e0eb7)
132. [Heier et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/23084240/)
133. [Heier et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35085502/)
134. [Hernandez et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10397814/)
135. [Hernandez et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34340976/)
136. [Holekamp et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24388973/)
137. [Holekamp et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34597713/)
138. [Holekamp et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38679018/)
139. [Holz et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4316940/)
140. [Holz et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5256408/)
141. [Holz et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7773197/)
142. [Holz et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/33957183/)
143. [Hutton et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4137040/)
144. [Hwang et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36717001/)
145. [Javitt et al. (2003)](https://pubmed.ncbi.nlm.nih.gov/12917168/)
146. [Jung et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25034111/)
147. [Kahn et al. (2022)](https://investors.ocutx.com/static-files/784662d9-3fe7-4e4c-bc3e-8cc29027ccf0)
148. [Kertes et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6990694/)
149. [Khanani et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31812631/)
150. [Khanani et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35537533/)
151. [Khanani et al. (2023)](https://investors.ocutx.com/static-files/d429e653-115c-452a-9061-09095f31d018)
152. [Khanani et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38382813/)
153. [Khurana et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36858288/)
154. [Kiss et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25037010/)
155. [Kiss et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10390935/)
156. [Kiss et al. (2020b)](https://pubmed.ncbi.nlm.nih.gov/32345477/)
157. [Klein et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17270675/)
158. [Klein et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21220632/)
159. [Kuznik et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12534633/)
160. [Kvanta et al. (1996)](https://pubmed.ncbi.nlm.nih.gov/8759365/)
161. [Lanzetta et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38461841/)
162. [Lazzara et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11215076/)
163. [Li et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31712255/)
164. [Liu et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35240337/)
165. [Loewenstein et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11724828/)
166. [Løkken et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13353565/)
167. [Lotery et al. (2007)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2000983/)
168. [Macula Society Annual Meeting (2026)](https://investors.ocutx.com/static-files/743a7c05-bb7b-4dfd-9319-42246dc51d67)
169. [Macular Photocoagulation Study Group (1991)](https://pubmed.ncbi.nlm.nih.gov/1714270/)
170. [Maesa et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9291450/)
171. [Maguire et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3758381/)
172. [Managed Healthcare Executive (2026)](https://www.managedhealthcareexecutive.com/view/bevacizumab-surpasses-eylea-as-the-most-common-retinal-disease-injection-asrs-2026)
173. [McGuinness et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28139151/)
174. [McGuire et al. (2026)](https://retinatoday.com/articles/2026-may-june/anti-vegf-step-therapy-an-update)
175. [MedPAC Data Book (2025)](https://www.medpac.gov/wp-content/uploads/2025/07/July2025_MedPAC_DataBook_Sec10_SEC-1.pdf)
176. [MedPAC Data Book (2026)](https://www.medpac.gov/wp-content/uploads/2026/07/July2026_MedPAC_DataBook_Sec10_SEC.pdf)
177. [Mehta et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29305324/)
178. [Mehta et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7569079/)
179. [Mitchell et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/30303083/)
180. [Mitchell et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8384251/)
181. [Mohan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13013963/)
182. [Monés et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31743912/)
183. [Monés et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33207259/)
184. [Moshfeghi et al. (2021)](https://investors.ocutx.com/static-files/7fbcac09-dd2b-4111-a3f1-39a173e4d9e4)
185. [Moshfeghi et al. (2022a)](https://investors.ocutx.com/static-files/4f3a6196-0c4e-4582-8ff2-e0b500a86ee3)
186. [Moshfeghi et al. (2022b)](https://investors.ocutx.com/static-files/e81af7af-1b2b-45f4-8676-e47aa9c13774)
187. [Moshfeghi et al. (2023a)](https://investors.ocutx.com/static-files/d3dc4e34-2889-460a-acc2-b9e1f7528c1a)
188. [Moshfeghi et al. (2023b)](https://investors.ocutx.com/static-files/d0695936-40b7-4f96-b849-aaf136373d82)
189. [Moshfeghi et al. (2023c)](https://iovs.arvojournals.org/article.aspx?articleid=2786043)
190. [Mowatt et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4780940/)
191. [Nam and Yun (2025)](https://pubmed.ncbi.nlm.nih.gov/40111518/)
192. [Niazi et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31654492/)
193. [NICE (2018)](https://www.nice.org.uk/guidance/ng82/chapter/recommendations)
194. [NICE resource impact report (2022)](https://www.nice.org.uk/guidance/ta800/resources/resource-impact-report-pdf-11132496109)
195. [NICE TA800 committee discussion (2022)](https://www.nice.org.uk/guidance/ta800/chapter/3-Committee-discussion)
196. [NICE TA800 recommendations (2022)](https://www.nice.org.uk/guidance/ta800/chapter/1-Recommendations)
197. [Notal Vision (2024)](https://notalvision.com/assets/press-releases/May-16-2024-FDA-Grants-AI-Powered-Notal-Vision-Home-OCT-22SCANLY22-De-Novo-Marketing-Authorization.pdf)
198. [Obeid et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6583857/)
199. [Ocular Therapeutix 12-month U.S. phase 1 results announcement (2023)](https://www.globenewswire.com/news-release/2023/06/10/2685891/0/en/Ocular-Therapeutix-Announces-12-Month-Topline-Data-from-Ongoing-U-S-Based-Phase-1-Clinical-Trial-Evaluating-OTX-TKI-for-Treatment-of-Wet-AMD.html)
200. [Ocular Therapeutix additional Week 52 data announcement (2026)](https://www.globenewswire.com/news-release/2026/04/13/3272358/0/en/Ocular-Therapeutix-Announces-Additional-Positive-Week-52-Data-from-Landmark-SOL-1-Phase-3-Trial-of-AXPAXLI-in-Wet-AMD.html)
201. [Ocular Therapeutix first subjects screened announcement (2024)](https://www.globenewswire.com/news-release/2024/02/13/2828143/0/en/Ocular-Therapeutix-Announces-First-Subjects-Screened-in-Phase-3-Pivotal-Clinical-Trial-of-AXPAXLI-in-Wet-AMD.html)
202. [Ocular Therapeutix Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1393434/000110465926010664/ocul-20251231x10k.htm)
203. [Ocular Therapeutix Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1393434/000110465926089450/ocul-20260630x10q.htm)
204. [Ocular Therapeutix Investor Day announcement (2024)](https://www.globenewswire.com/news-release/2024/06/13/2898636/0/en/ocular-therapeutix-highlights-exceptional-axpaxli-sol-1-enrollment-and-plans-for-repeat-dosing-study-sol-r-in-wet-amd-at-investor-day-along-with-positive-48-week-data-from-helios-n.html)
205. [Ocular Therapeutix Investor Day announcement (2026)](https://www.globenewswire.com/news-release/2026/06/17/3313442/0/en/Ocular-Therapeutix-Investor-Day-to-Highlight-U-S-FDA-Alignment-on-AXPAXLI-NDA-with-Submission-Planned-for-Fourth-Quarter-2026.html)
206. [Ocular Therapeutix Investor Day presentation (2026)](https://investors.ocutx.com/static-files/f1bdaecb-850c-4418-84ac-217f3f60c314)
207. [Ocular Therapeutix NDA acceleration announcement (2025)](https://www.globenewswire.com/news-release/2025/12/08/3201405/0/en/Ocular-Therapeutix-Announces-Plans-to-Accelerate-NDA-Submission-Timeline-for-AXPAXLI-in-Wet-AMD.html)
208. [Ocular Therapeutix pre-NDA meeting announcement (2026)](https://www.globenewswire.com/news-release/2026/09/15/3361910/0/en/ocular-therapeutix-announces-positive-pre-nda-meeting-with-u-s-fda-for-axpaxli-in-wet-amd.html)
209. [Ocular Therapeutix second-quarter 2026 results announcement (2026)](https://www.globenewswire.com/news-release/2026/08/03/3337365/0/en/Ocular-Therapeutix-Reports-Second-Quarter-2026-Financial-Results-and-Business-Highlights.html)
210. [Ocular Therapeutix SOL-1 randomization announcement (2024)](https://www.globenewswire.com/news-release/2024/12/02/2989687/0/en/Ocular-Therapeutix-Announces-More-Than-300-Subjects-Randomized-in-SOL-1.html)
211. [Ocular Therapeutix SOL-1 topline results announcement (2026)](https://www.globenewswire.com/news-release/2026/02/17/3239086/0/en/ocular-therapeutix-reports-positive-results-from-landmark-sol-1-phase-3-superiority-trial-in-wet-amd.html)
212. [Ocular Therapeutix SOL-R enrollment closing announcement (2025)](https://www.globenewswire.com/news-release/2025/05/28/3089319/0/en/Ocular-Therapeutix-To-Close-Enrollment-This-Week-for-SOL-R-its-Second-Registrational-Trial-Evaluating-AXPAXLI-in-Wet-Age-Related-Macular-Degeneration.html)
213. [Ocular Therapeutix SOL-R enrollment progress announcement (2025)](https://www.globenewswire.com/news-release/2025/01/14/3009162/0/en/Ocular-Therapeutix-Shares-SOL-R-Enrollment-Progress-and-Next-Steps-for-AXPAXLI-in-NPDR.html)
214. [Ocular Therapeutix SOL-R FDA feedback announcement (2024)](https://www.globenewswire.com/news-release/2024/08/07/2925816/0/en/Ocular-Therapeutix-Announces-FDA-Feedback-That-SOL-R-Trial-is-Appropriate-as-a-Registrational-Study-in-Wet-AMD.html)
215. [Ocular Therapeutix SOL-R target randomization announcement (2025)](https://www.globenewswire.com/news-release/2025/11/04/3180122/0/en/Ocular-Therapeutix-Achieves-Target-Randomization-of-555-Subjects-in-SOL-R.html)
216. [Ocular Therapeutix SOL-X first patient announcement (2026)](https://www.globenewswire.com/news-release/2026/04/29/3283623/0/en/ocular-therapeutix-announces-first-patient-enrolled-in-sol-x-long-term-extension-trial-for-axpaxli-in-wet-amd.html)
217. [Ocular Therapeutix SPA agreement announcement (2023)](https://www.globenewswire.com/news-release/2023/11/01/2771115/0/en/Ocular-Therapeutix-Receives-FDA-Agreement-Under-Special-Protocol-Assessment-SPA-for-its-First-Pivotal-Clinical-Trial-of-OTX-TKI-in-Wet-AMD.html)
218. [Ocular Therapeutix SPA amendment announcement (2024)](https://www.globenewswire.com/news-release/2024/01/25/2816690/0/en/Ocular-Therapeutix-Announces-FDA-Agreement-to-Amend-Special-Protocol-Assessment-SPA-for-Pivotal-Clinical-Trial-of-AXPAXLI-in-Wet-AMD.html)
219. [Ocular Therapeutix third-quarter 2026 results announcement (2026)](https://www.globenewswire.com/news-release/2026/11/09/3398240/0/en/ocular-therapeutix-reports-third-quarter-2026-financial-results-and-business-highlights.html)
220. [Ocular Therapeutix treatment burden analysis presentation (2026)](https://investors.ocutx.com/static-files/1e6ac653-a838-4133-8c7f-95d0422e3c21)
221. [Ohji et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7089719/)
222. [Okada et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7403101/)
223. [Patel (2018)](https://pubmed.ncbi.nlm.nih.gov/31047530/)
224. [Patel and Sternberg (2022b)](https://pubmed.ncbi.nlm.nih.gov/35708666/)
225. [Patel et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/20846318/)
226. [Patel et al. (2022a)](https://investors.ocutx.com/static-files/bce31b1a-f817-490a-9409-84d729967d6f)
227. [Patel et al. (2024)](https://investors.ocutx.com/static-files/7ba88c7f-fe2f-4561-9b0d-7fc8a7b1b07a)
228. [Patel et al. (2025)](https://investors.ocutx.com/static-files/42ec39ff-94fc-466f-94d8-595f2227a4d1)
229. [Patil et al. (2024)](https://investors.ocutx.com/static-files/1da7a731-ff35-448d-b39c-943d4c93d1cf)
230. [Paudel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12316190/)
231. [Pearson et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/24004384/)
232. [Peto et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35314388/)
233. [Pitsillidou et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42627194/)
234. [Prenner et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26142721/)
235. [Quist et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11868297/)
236. [Rao et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29146306/)
237. [REGENXBIO second-quarter 2026 results announcement (2026)](https://ir.regenxbio.com/news-releases/news-release-details/regenxbio-reports-second-quarter-2026-financial-results-and)
238. [Rein et al. (2022a)](https://pubmed.ncbi.nlm.nih.gov/34560128/)
239. [Rein et al. (2022b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9634594/)
240. [Reitan et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10226541/)
241. [Review of Ophthalmology (2022)](https://www.reviewofophthalmology.com/article/retina-surgeons-share-their-treatment-preferences)
242. [Robinson et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12341839/)
243. [Rofagha et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23642856/)
244. [Rosenfeld et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/17021318/)
245. [Rosenfeld et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29655642/)
246. [Rovner et al. (2002)](https://pubmed.ncbi.nlm.nih.gov/12149057/)
247. [Rovner et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17679633/)
248. [Rovner et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4253064/)
249. [Rowe et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12360407/)
250. [Rudnicka et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25857680/)
251. [Schlottmann (2025)](https://investors.ocutx.com/static-files/d9e143a4-4054-4ade-9ad3-edcebbaba93f)
252. [Schlottmann et al. (2026)](https://investors.ocutx.com/static-files/5ce1f26a-7745-4fa7-9bcf-dc89a03421cd)
253. [Schmidt-Erfurth et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4145443/)
254. [Schmier et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/17151494/)
255. [Schuster et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10299675/)
256. [Senra et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27262729/)
257. [Senra et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28302534/)
258. [Sheth et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41092160/)
259. [Shirian et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11733175/)
260. [Siddiqui et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10373014/)
261. [Siedlecki et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28161830/)
262. [Siedlecki et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29721663/)
263. [Singh and Sørensen (2012)](https://pubmed.ncbi.nlm.nih.gov/21106047/)
264. [Sivaprasad et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38814914/)
265. [Sobolewska et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8558036/)
266. [Solomon et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6419319/)
267. [Sood et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9204613/)
268. [Soubrane et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17846366/)
269. [Spaide et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11559632/)
270. [Spooner et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6287411/)
271. [Spooner et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12516669/)
272. [Spooner et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41223128/)
273. [Stein et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4109727/)
274. [Stelmack et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18474769/)
275. [Suñer et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19255158/)
276. [TAP Study Group (1999)](https://pubmed.ncbi.nlm.nih.gov/10532441/)
277. [TipRanks (2026)](https://www.tipranks.com/news/the-fly/ocular-therapeutix-price-target-raised-to-31-from-21-at-piper-sandler-thefly)
278. [Tran et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11067424/)
279. [Tsang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10870181/)
280. [Tufail et al. (2026)](https://investors.ocutx.com/static-files/10acbc21-4940-41c9-b817-33815cfa4674)
281. [UnitedHealthcare Medicare Part B Step Therapy Programs (2026)](https://www.uhcprovider.com/content/dam/provider/docs/public/policies/index/mamp/medicare-part-b-step-therapy-programs-01012026.pdf)
282. [Varano et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4671808/)
283. [Vemulakonda et al. (2025)](https://www.aao.org/Assets/f832e5ac-c047-4d1c-bdab-c5e52173623d/638760137410500000/age-related-macular-degeneration-ppp-pdf)
284. [Vinge and Bro (2024)](https://pubmed.ncbi.nlm.nih.gov/37800611/)
285. [Viola et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39208778/)
286. [Violato et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5093395/)
287. [Vision Loss Expert Group of the Global Burden of Disease Study (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11269688/)
288. [Vit-Buckle Society Annual Meeting (2026)](https://investors.ocutx.com/static-files/25f7136d-a534-4d93-8884-614e88408879)
289. [Vitale et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7146539/)
290. [Vukicevic et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4791694/)
291. [WHO Collaborating Centre for Drug Statistics Methodology ATC/DDD Index L01EK01 (2026)](https://atcddd.fhi.no/atc_ddd_index/?code=L01EK01)
292. [WHO Collaborating Centre for Drug Statistics Methodology ATC/DDD Index S01LA (2026)](https://atcddd.fhi.no/atc_ddd_index/?code=S01LA)
293. [Wibbelsman et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31265802/)
294. [Willmington et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12922378/)
295. [Windsor et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5732022/)
296. [Wong et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/17675159/)
297. [Wong et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25104651/)
298. [Wong et al. (2021a)](https://investors.ocutx.com/static-files/3c59d3b0-9995-4e63-a972-e233a7550b1b)
299. [Wong et al. (2021b)](https://iovs.arvojournals.org/article.aspx?articleid=2773001)
300. [Woo et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7677876/)
301. [Wood et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21474773/)
302. [Wykoff et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/31047517/)
303. [Wykoff et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/28779006/)
304. [Wykoff et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10767511/)
305. [Wykoff et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11418737/)
306. [Xin et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/28665868/)
307. [Zarranz-Ventura et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24953791/)
308. [Zhang et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37116720/)

## Related pages
- [AXPAXLI (axitinib intravitreal implant): Neovascular age-related macular degeneration](https://www.evicenter.com/drugs/axpaxli--neovascular-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/axpaxli--neovascular-age-related-macular-degeneration.md)
- [AXPAXLI (axitinib intravitreal implant) in Neovascular age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/axpaxli--neovascular-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/axpaxli--neovascular-age-related-macular-degeneration/terms-and-abbreviations.md)
- [AXPAXLI (axitinib intravitreal implant): Neovascular age-related macular degeneration](https://www.evicenter.com/drugs/axpaxli--neovascular-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/axpaxli--neovascular-age-related-macular-degeneration/executive-summary.md)
- [AXPAXLI (axitinib intravitreal implant) in Neovascular age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/axpaxli--neovascular-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/axpaxli--neovascular-age-related-macular-degeneration/product-information-and-disease-description.md)
- [AXPAXLI (axitinib intravitreal implant) in Neovascular age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/axpaxli--neovascular-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/axpaxli--neovascular-age-related-macular-degeneration/clinical-evidence.md)
- [AXPAXLI (axitinib intravitreal implant) in Neovascular age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/axpaxli--neovascular-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/axpaxli--neovascular-age-related-macular-degeneration/economics.md)
- [AXPAXLI (axitinib intravitreal implant) in Neovascular age-related macular degeneration: prevalence by geography](https://www.evicenter.com/drugs/axpaxli--neovascular-age-related-macular-degeneration/prevalence) · [Markdown](https://www.evicenter.com/drugs/axpaxli--neovascular-age-related-macular-degeneration/prevalence.md)
- [AXPAXLI (axitinib intravitreal implant) in Neovascular age-related macular degeneration: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/axpaxli--neovascular-age-related-macular-degeneration/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/axpaxli--neovascular-age-related-macular-degeneration/cost-effectiveness-analyses.md)
